The company provides products to the U.S. hospital market, including Angiomax, an anticoagulant drug used during angioplasty, and Cleviprex, a drug designed to control blood pressure in intensive-care settings. The Medicines Company also has two products in late-stage development: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. Additionally, the company is working on an early-stage development project called CU2010, a serine protease inhibitor. Recently, The Medicines Company was acquired by Novartis.